18F - 多巴PET和PET/CT - Suppr

Suppr

超能文献

18F-DOPA PET and PET/CT.

作者信息

Nanni Cristina, Fanti Stefano, Rubello Domenico

机构信息

S. Orsola-Malpighi Hospital, Bologna, Italy.

出版信息

J Nucl Med. 2007 Oct;48(10):1577-9. doi: 10.2967/jnumed.107.041947.

DOI:10.2967/jnumed.107.041947

PMID:17909255

Abstract

摘要

相似文献

18F-DOPA PET and PET/CT.

J Nucl Med. 2007 Oct;48(10):1577-9. doi: 10.2967/jnumed.107.041947.

Current status and future challenges of brain imaging with (18)F-DOPA PET for movement disorders.

Hell J Nucl Med. 2016 Jan-Apr;19(1):33-41. doi: 10.1967/s002449910335. Epub 2016 Mar 1.

Advances in PET. Part I. Foreword.

Q J Nucl Med Mol Imaging. 2007 Sep;51(3):213.

18F-DOPA PET/CT biodistribution consideration in 107 consecutive patients with neuroendocrine tumours.

Nucl Med Commun. 2012 Feb;33(2):179-84. doi: 10.1097/MNM.0b013e32834e0974.

Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.

Nucl Med Commun. 2007 Jun;28(6):473-7. doi: 10.1097/MNM.0b013e328182d606.

[Clarification of intermittent diarrhea using Positron-Emission-Tomography (PET) and CT-X-ray].

Versicherungsmedizin. 2007 Sep 1;59(3):149.

Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients.

J Clin Endocrinol Metab. 2007 Apr;92(4):1237-44. doi: 10.1210/jc.2006-1479. Epub 2007 Jan 16.

18F-DOPA PET/CT and neuroendocrine tumours.

Eur J Nucl Med Mol Imaging. 2006 May;33(5):509-13. doi: 10.1007/s00259-006-0079-5.

PET-CT--comments on the white paper.

Eur J Nucl Med Mol Imaging. 2008 Aug;35(8):1576. doi: 10.1007/s00259-008-0844-8.

Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.

Br J Surg. 2010 May;97(5):691-7. doi: 10.1002/bjs.6937.

引用本文的文献

Development of the First F-Labeled Radiohybrid-Based Minigastrin Derivative with High Target Affinity and Tumor Accumulation by Substitution of the Chelating Moiety.

Pharmaceutics. 2023 Mar 3;15(3):826. doi: 10.3390/pharmaceutics15030826.

Translational molecular imaging and drug development in Parkinson's disease.

Mol Neurodegener. 2023 Feb 10;18(1):11. doi: 10.1186/s13024-023-00600-z.

Assessment of the anti-nociceptive effects of fetal ventral mesencephalic tissue allografts in a rat model of hemi-Parkinson's disease using fMRI.

Front Aging Neurosci. 2022 Nov 18;14:948848. doi: 10.3389/fnagi.2022.948848. eCollection 2022.

The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research.

Pharmaceutics. 2021 Aug 6;13(8):1214. doi: 10.3390/pharmaceutics13081214.

Pharmacokinetic Modeling of F-FDOPA PET in the Human Brain for Early Parkinson's Disease.

Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):69-78. doi: 10.4274/mirt.galenos.2021.08831.

The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:49-53. doi: 10.1016/j.pnpbp.2015.08.013. Epub 2015 Sep 1.

PET-specific parameters and radiotracers in theoretical tumour modelling.

Comput Math Methods Med. 2015;2015:415923. doi: 10.1155/2015/415923. Epub 2015 Feb 19.

Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings.

Neurosci Bull. 2014 Oct;30(5):765-76. doi: 10.1007/s12264-014-1469-5. Epub 2014 Sep 28.

Regional, kinetic [(18)F]FDG PET imaging of a unilateral Parkinsonian animal model.

Am J Nucl Med Mol Imaging. 2013;3(2):129-41. Epub 2013 Mar 8.

Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.

Eur Radiol. 2011 Feb;21(2):256-64. doi: 10.1007/s00330-010-1930-4. Epub 2010 Aug 15.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验